ChemicalBook > CAS DataBase List > CFI-400945

CFI-400945

Product Name
CFI-400945
CAS No.
1338806-73-7
Chemical Name
CFI-400945
Synonyms
CFI-400945;ocifisertib;CFI-400945 (CFI400945;CFI-400945 (free base);Ocifisertib(CFI-400945 free base);CFI400945 free base,CFI 400945 free base;Ocifisertib(CFI-400945 free base), 10 mM in DMSO;(1R,2S)-2-(3-((E)-4-(((2R,6S)-2,6-Dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one;(1R,2S)-2-[3-[(E)-2-[4-[[(2S,6R)-2,6-dimethylmorpholin-4-yl]methyl]phenyl]vinyl]-1H-indazol-6-yl]-5'-methoxy-spiro[cyclopropane-1,3'-indoline]-2'-one;Spiro[cyclopropane-1,3'-[3H]indol]-2'(1'H)-one, 2-[3-[(1E)-2-[4-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]phenyl]ethenyl]-1H-indazol-6-yl]-5'-methoxy-, (1R,2S)-
CBNumber
CB92716177
Molecular Formula
C33H34N4O3
Formula Weight
534.65
MOL File
1338806-73-7.mol
More
Less

CFI-400945 Property

Boiling point:
751.5±60.0 °C(Predicted)
Density 
1.32±0.1 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
insoluble in H2O; ≥109.8 mg/mL in DMSO; ≥93 mg/mL in EtOH
form 
crystalline solid
pka
13.09±0.40(Predicted)
color 
White to yellow
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

ApexBio Technology
Product number
C5813
Product name
CFI-400945
Packaging
5mg
Price
$154
Updated
2021/12/16
ApexBio Technology
Product number
C5813
Product name
CFI-400945
Packaging
10mM(in 1mL DMSO)
Price
$182
Updated
2021/12/16
ApexBio Technology
Product number
C5813
Product name
CFI-400945
Packaging
10mg
Price
$257
Updated
2021/12/16
Biorbyt Ltd
Product number
orb611612
Product name
CFI-400945
Packaging
100mg
Price
$765
Updated
2021/12/16
ApexBio Technology
Product number
C5813
Product name
CFI-400945
Packaging
50mg
Price
$926
Updated
2021/12/16
More
Less

CFI-400945 Chemical Properties,Usage,Production

Uses

(1R,?2S)?-2-?[3-?[(1E)?-?2-?[4-?[[(2R,?6S)?-?2,?6-?Dimethyl-?4-?morpholinyl]?methyl]?phenyl]?ethenyl]?-?1H-?indazol-?6-?yl]?-?5''-?methoxy-?spiro[cyclopropane-?1,?3''-?[3H]?indol]?-?2''(1''H)?-?one selectively inhibits polo-like kinase 4 (PLK4), which is a serine/threonine protein kinase that regulates centriole duplication during the cell cycle. PLK4 is a therapeutic target for various cancers.

Biological Activity

cfi-400945 is an orally active, potent and selective inhibitor of polo-like kinase 4.polo-like kinase 4 (plk4), a unique member of the polo-like family of kinases, shares little homology with other polo-like kinases. plk4 plays an essential role in centriole duplication. overexpression of plk4 overrides the centriole licensing mechanism and results in centriole amplification with multiple procentrioles forming around each parental centriole. depletion of plk4 by rnai prevents the formation of abnormal centrioles and microtubule-based structures, causing mitotic defects and in some cell lines it can induce apoptosis [2].in an assay using recombinant human plk4, cfi-400945 inhibited plk4 with an ic50 value of 2.8 ± 1.4 nm in an atp competitive manner with a ki value of 0.26 ± 0.1 nm. cfi-400945 inhibited autophosphorylation of plk4 at serine 305 with an ec50 value of 12.3 nm in cells overexpressing plk4 [1]. cfi-400945 showed no significant inhibitory activity against other plk family members (plk1, plk2, and plk3 with the ic50s of > 50 μm. in transfected hct116 cells with trka, trkb, and tie2/tek, the ec50 values were 84 nm, 88 nm, and 117 nm, respectively. cfi-400945 inhibited the activity of aurka and aurkb with the ec50 value of 510 nm and 102 nm. cfi-400945 (≥ 200 nm) decreased the mean centriole number in asynchronous u2os cells [1]. cfi-400945 inhibited a panel of breast cancer cell growth with the gi50 of 14-165 nm. in mice, the maximum tolerated dose (mtd) of cfi-400945 for once-daily oral administration was estimated to be 7.5-9.5 mg/kg [1].

References

[1] mason j m, lin d c c, wei x, et al. functional characterization of cfi-400945, a polo-like kinase 4 inhibitor, as a potential anticancer agent[j]. cancer cell, 2014, 26(2): 163-176.
[2] sillibourne j e, bornens m. polo-like kinase 4: the odd one out of the family[j]. cell division, 2010, 5(1): 25.

CFI-400945 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

CFI-400945 Suppliers

Musechem
Tel
+1-800-259-7612
Fax
+1-800-259-7612
Email
info@musechem.com
Country
United States
ProdList
4660
Advantage
60
TargetMol Chemicals Inc.
Tel
+1-781-999-5354 +1-00000000000
Email
marketing@targetmol.com
Country
United States
ProdList
32159
Advantage
58
InvivoChem
Tel
+1-708-310-1919 +1-13798911105
Fax
708-557-7486
Email
sales@invivochem.cn
Country
United States
ProdList
6391
Advantage
58
Aladdin Scientific
Tel
Email
tp@aladdinsci.com
Country
United States
ProdList
57505
Advantage
58
TargetMol Chemicals Inc.
Tel
Email
support@targetmol.com
Country
United States
ProdList
38630
Advantage
58
ApexBio Technology
Tel
--
Fax
--
Email
sales@apexbt.com
Country
United States
ProdList
6251
Advantage
58

1338806-73-7, CFI-400945Related Search:


  • CFI-400945
  • CFI-400945 (free base)
  • CFI-400945 (CFI400945
  • Spiro[cyclopropane-1,3'-[3H]indol]-2'(1'H)-one, 2-[3-[(1E)-2-[4-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]phenyl]ethenyl]-1H-indazol-6-yl]-5'-methoxy-, (1R,2S)-
  • ocifisertib
  • CFI400945 free base,CFI 400945 free base
  • (1R,2S)-2-[3-[(E)-2-[4-[[(2S,6R)-2,6-dimethylmorpholin-4-yl]methyl]phenyl]vinyl]-1H-indazol-6-yl]-5'-methoxy-spiro[cyclopropane-1,3'-indoline]-2'-one
  • Ocifisertib(CFI-400945 free base)
  • (1R,2S)-2-(3-((E)-4-(((2R,6S)-2,6-Dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one
  • Ocifisertib(CFI-400945 free base), 10 mM in DMSO
  • 1338806-73-7
  • 338806-73-7
  • API